NewAmsterdam PharmaNAMS
About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Employees: 68
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
98% more capital invested
Capital invested by funds: $1.28B [Q3] → $2.53B (+$1.25B) [Q4]
60% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 8 (+3) [Q4]
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
30% more funds holding
Funds holding: 100 [Q3] → 130 (+30) [Q4]
8.73% more ownership
Funds ownership: 85.64% [Q3] → 94.37% (+8.73%) [Q4]
35% less call options, than puts
Call options by funds: $8.11M | Put options by funds: $12.6M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Serge Belanger 40% 1-year accuracy 49 / 123 met price target | 143%upside $42 | Buy Reiterated | 8 Apr 2025 |
Scotiabank George Farmer 14% 1-year accuracy 3 / 21 met price target | 201%upside $52 | Sector Outperform Maintained | 27 Feb 2025 |
RBC Capital Brian Abrahams 6% 1-year accuracy 4 / 69 met price target | 132%upside $40 | Outperform Reiterated | 28 Jan 2025 |
RBC Capital Leonid Timashev 12% 1-year accuracy 5 / 41 met price target | 132%upside $40 | Outperform Reiterated | 24 Jan 2025 |
Financial journalist opinion









